AVRO vs. LENZ, GNTA, CDTX, ALGS, IKNA, TSBX, TARA, INAB, DYAI, and ENTX
Should you be buying AVROBIO stock or one of its competitors? The main competitors of AVROBIO include LENZ Therapeutics (LENZ), Genenta Science (GNTA), Cidara Therapeutics (CDTX), Aligos Therapeutics (ALGS), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Protara Therapeutics (TARA), IN8bio (INAB), Dyadic International (DYAI), and Entera Bio (ENTX). These companies are all part of the "medical" sector.
AVROBIO (NASDAQ:AVRO) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
In the previous week, AVROBIO and AVROBIO both had 6 articles in the media. AVROBIO's average media sentiment score of 1.13 beat LENZ Therapeutics' score of 0.80 indicating that AVROBIO is being referred to more favorably in the media.
62.6% of AVROBIO shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 9.2% of AVROBIO shares are owned by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
LENZ Therapeutics' return on equity of -39.55% beat AVROBIO's return on equity.
AVROBIO has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500.
AVROBIO currently has a consensus price target of $2.00, suggesting a potential upside of 45.99%. LENZ Therapeutics has a consensus price target of $31.33, suggesting a potential upside of 59.70%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than AVROBIO.
AVROBIO received 167 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 66.93% of users gave AVROBIO an outperform vote.
Summary
LENZ Therapeutics beats AVROBIO on 7 of the 12 factors compared between the two stocks.
Get AVROBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
